SHIELD THERAPEUTICS PLC
A specialty pharmaceutical company focused on addressing iron deficiency in adults.
STX | IL
Overview
Corporate Details
- ISIN(s):
- GB00BYV81293
- LEI:
- 213800G74QWY15FC3W71
- Country:
- United Kingdom
- Address:
- NORTHERN DESIGN CENTRE STUDIO 6, 3RD FLOOR, NE8 3DF GATESHEAD
- Sector:
- Manufacturing
Description
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-11 08:25 |
Shield Wins Gold at Titan Branding Awards
|
English | 12.0 KB | ||
| 2025-12-03 08:45 |
Amends Senior Secured Debt Financing
|
English | 18.0 KB | ||
| 2025-11-14 08:40 |
Initiation of a Phase II Clinical Trial in Japan
|
English | 19.2 KB | ||
| 2025-11-11 08:25 |
ACCRUFeR Pediatric PK Results to be Presented
|
English | 20.2 KB | ||
| 2025-11-07 08:40 |
ACCRUFeR receives Authorisation by Korean Ministry
|
English | 16.2 KB | ||
| 2025-10-14 16:01 |
Grant of Share Options to Chief Executive Officer
|
English | 26.5 KB | ||
| 2025-10-01 09:00 |
Total Voting Rights
|
English | 13.5 KB | ||
| 2025-10-01 08:02 |
Positive efficacy and tolerance in pediatric trial
|
English | 18.7 KB | ||
| 2025-09-15 08:00 |
£1.5 million placing supporting growth of ACCRUFeR
|
English | 18.2 KB | ||
| 2025-08-27 08:13 |
Data published -European Journal of Heart Failure
|
English | 21.9 KB | ||
| 2025-08-21 13:06 |
Interim results for the six months ended 30 Jun 25
|
English | 245.5 KB | ||
| 2025-05-22 11:40 |
Shield Therapeutics plc 2024 Annual Report and Accounts
|
English | 4.4 MB | ||
| 2025-04-22 08:01 |
Licence Agreement in Japan for ACCRUFeR®
|
English | 22.9 KB | ||
| 2025-03-11 08:00 |
ACCRUFeR® launched in Canada
|
English | 21.0 KB | ||
| 2025-02-13 17:15 |
PDMR Transaction Notification
|
English | 28.6 KB |
Automate Your Workflow. Get a real-time feed of all SHIELD THERAPEUTICS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SHIELD THERAPEUTICS PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SHIELD THERAPEUTICS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
